The compounded weight-loss injections advertised for a few hundred dollars a month are frequently not chemically identical to the drugs that were studied in clinical trials. Some contain a different molecular form of the active ingredient. Many contain added substances that have no established weight-loss benefit and that have never been tested in combination with a GLP-1 medication in humans.
That is the assessment Stanford Medicine clinicians laid out in guidance published this month, aimed at the large number of Americans who turned to compounding pharmacies for cost reasons. At the 2024 peak, close to one in three people taking a GLP-1 drug in the United States reported obtaining it from a compounder.
The concern is not abstract for household budgets. Brand-name GLP-1 medications can list above $1,000 a month, and generic semaglutide is not expected in the United States until at least 2032. Cost is why people use compounded products, and any honest account of the risks has to sit alongside that reality.
Why a Salt Form Is Not the Same Drug
The semaglutide and tirzepatide in FDA-approved products have a specific chemical structure that was carried through the pivotal trials. Some compounders instead use chemically distinct versions known as salt forms, such as semaglutide sodium, in which a sodium salt is attached to the molecule.
These salt forms have not been shown safe and effective in humans and are not FDA-approved. Marina Basina, MD, a clinical professor in endocrinology, gerontology and metabolism at Stanford Medicine, noted that effectiveness "can be different due to the salt form differences."
Formulation is a parallel issue. Semaglutide and tirzepatide are approved as injectables, with one approved oral semaglutide tablet. Sublingual drops and dissolving tablets sold by some compounders have never been evaluated in clinical trials. Michael Blyumin, PharmD, an ambulatory clinical care pharmacist at Stanford Medicine, put it bluntly: "Nobody legitimate makes sublingual semaglutide."
The B12 Problem and What a 2026 Analysis Found
To argue that their products are meaningfully different from the approved drugs, many compounders add extra ingredients. Vitamin B12 is the most common, along with B6, niacinamide, glycine and carnitine. None has proven benefit for weight loss or diabetes management, and the combinations are largely untested.
A laboratory analysis published in Expert Opinion on Drug Safety on April 30, 2026, examined samples of compounded tirzepatide mixed with B12 obtained from various sources in the U.S. market. The authors identified a previously uncharacterized impurity, an adduct formed by a chemical reaction between tirzepatide and B12, present at significant levels and absent from FDA-approved tirzepatide.
The limitation belongs in the same breath as the finding. This was analytical chemistry on marketed product samples, not a clinical study. The authors state directly that whether the adduct alters receptor binding, distribution, immune response, or other aspects of the drug's behavior remains unknown. No patient harm has been attributed to it.
Eli Lilly, which manufactures tirzepatide, said it replicated the finding and published an open letter calling for a nationwide recall of tirzepatide products containing untested additives. Readers should weigh that the company is the commercial competitor of the compounders it is describing. Its central factual claim, that the combination has never been studied and that compounders are not required to monitor or report adverse events, is independently supportable.
Separate academic work supports the broader pattern. An analysis published in Annals of Pharmacotherapy by researchers including C. Michael White at the University of Connecticut identified 33 unique compounded products and found that 48 percent combined semaglutide or tirzepatide with additives such as cyanocobalamin, glycine, niacinamide or docusate. The authors found little justification for adding nutrients or docusate to injectable products.
Dosing Errors and Why Vials Are Riskier Than Pens
Ingredient composition is not the only difference. Approved GLP-1 products come in prefilled, single-dose pens with fixed increments. Many compounded versions arrive as multidose vials that require the patient to draw a dose with a syringe.
The FDA has flagged cases in which patients inadvertently administered 10 to 20 times the intended amount while measuring from a vial. Concentrations also vary between products, so the same number of syringe units can deliver very different quantities of drug. Poison control centers have recorded more than a fifteen-fold increase in calls involving injected weight-loss drugs since 2019.
Peptide stability adds a third layer. GLP-1 drugs are short amino acid chains that degrade when exposed to heat, light or poor handling. A degraded product may simply be less potent, with no visible sign.
What the FDA Is Doing and What Changes for Patients
Tirzepatide came off the FDA shortage list in December 2024 and semaglutide in February 2025, which removed the legal basis for compounding copies of the approved drugs. On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulk List, the set of ingredients large-scale outsourcing facilities may use. The comment period was extended into late July.
The agency has separately issued warning letters to 30 telehealth companies for false or misleading claims, including marketing that implied their compounded products were the same as approved drugs.
Nothing changes immediately. If finalized, the proposal would apply to 503B outsourcing facilities. Smaller 503A pharmacies could still prepare patient-specific versions, but only for a narrow set of clinical reasons rather than routine prescriptions. Patients using approved products including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda and Victoza are unaffected.
What Patients Taking a Compounded GLP-1 Should Do
Do not stop abruptly on your own, particularly if the medication is treating diabetes. Both Stanford clinicians emphasized that point. Bring the question to a clinician and ask specifically about lower-cost approved options, including manufacturer direct-purchase pricing, Medicare out-of-pocket protections where applicable, and older generic weight-loss medications.
Switching is not always simple, because the true dose delivered by a compounded product may be unclear. Basina's guidance for that transition was to begin below the reported compounded dose and increase slowly under supervision.
Warning signs worth prompt medical attention while on any compounded product include signs of severe dehydration such as fainting, confusion or not urinating for eight hours, sharp upper abdominal pain radiating to the back, and gastrointestinal symptoms that worsen over time or fail to improve with smaller meals.
Red flags about the seller itself include a product sold without a prescription, a pharmacy located outside the United States, packaging that is damaged or lacks an expiration date, sublingual or dissolving formats, and vague proprietary ingredient blends. The FDA's BeSafeRx program can help verify whether an online pharmacy is licensed in your state.
Frequently Asked Questions
What happened? Clinicians and researchers have documented that many compounded GLP-1 products use unapproved salt forms of the active drug or add ingredients such as vitamin B12 that were never tested in humans alongside these medications.
What is a salt form and why does it matter? It is a chemically distinct version of the drug, such as semaglutide sodium. These forms were not used in the clinical trials that established safety and effectiveness, and their performance may differ.
What did the 2026 analysis find? Laboratory testing of market samples found that tirzepatide combined with B12 can form a new molecule not present in the approved drug. The clinical significance of that molecule is unknown, and no patient harm has been attributed to it.
Is anyone known to have been harmed? No harm has been linked to the adduct specifically. Separately, the FDA has documented dosing errors with multidose vials in which patients received far more drug than intended.
Should patients stop taking a compounded GLP-1? No one should stop or change a prescription on their own, especially for diabetes. Speak with a clinician about approved lower-cost alternatives and a supervised transition.
Will compounded GLP-1s become unavailable? Not immediately. The FDA has proposed excluding these ingredients from the 503B Bulks List used by large outsourcing facilities. Smaller 503A pharmacies could still compound patient-specific versions for narrow reasons.
How can someone tell if an online seller is unsafe? Warning signs include no prescription required, a non-U.S. pharmacy location, damaged packaging or no expiration date, sublingual or dissolving formats, and unexplained proprietary ingredient blends.
